PMC:7060195 / 2815-3870
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 52 | 869-875 | Species | denotes | humans | Tax:9606 |
| 53 | 902-910 | Disease | denotes | toxicity | MESH:D064420 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T5 | 764-767 | Body_part | denotes | DNA | http://purl.org/sig/ont/fma/fma74412 |
| T6 | 914-918 | Body_part | denotes | mRNA | http://purl.org/sig/ont/fma/fma67122 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T21 | 135-140 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T22 | 288-293 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T23 | 869-875 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T7 | 625-634 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
| T8 | 764-767 | Chemical | denotes | DNA | http://purl.obolibrary.org/obo/CHEBI_16991 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 334-350 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
| T3 | 504-528 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune responses |
| T4 | 697-721 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune responses |
| T5 | 849-865 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
| T6 | 989-1005 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T21 | 0-69 | Sentence | denotes | Table 1 Advantages and disadvantages of different vaccine strategies. |
| T22 | 70-122 | Sentence | denotes | Vaccine strategy Advantages Disadvantages References |
| T23 | 123-276 | Sentence | denotes | Inactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25 |
| T24 | 277-426 | Sentence | denotes | Attenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25 |
| T25 | 427-640 | Sentence | denotes | Subunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14 |
| T26 | 641-763 | Sentence | denotes | Viral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12 |
| T27 | 764-913 | Sentence | denotes | DNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23 |
| T28 | 914-1055 | Sentence | denotes | mRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23 |